UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Opportunities and Pitfalls of Corporate Social Responsibility: The Marange Diamond Mines Case Study

1st ed. 2019., 2019

Volltextzugriff (PDF)

Lessons in Financial Governance from Bowen’s Family Systems Model

Corporate Social Responsibility in a Dynamic Global Environment, 2023, p.305-318

2023

Volltextzugriff (PDF)

Environmental Impact and CSR Responsibilities

Opportunities and Pitfalls of Corporate Social Responsibility, 2019, p.151-168

2019

Volltextzugriff (PDF)

The Socio-economic Impact of Corporate Social Responsibility on the Zimbabwe Mining Industry

Opportunities and Pitfalls of Corporate Social Responsibility, 2019, p.49-71

2019

Volltextzugriff (PDF)

CSR Implementation Challenges: Analysing the Role and Behaviour of Stakeholders

Opportunities and Pitfalls of Corporate Social Responsibility, 2019, p.15-34

2019

Volltextzugriff (PDF)

Labour Management Issues in Marange Diamond Mines

Opportunities and Pitfalls of Corporate Social Responsibility, 2019, p.115-122

2019

Volltextzugriff (PDF)

Opportunities and Pitfalls of Corporate Social Responsibility: An Introduction

Opportunities and Pitfalls of Corporate Social Responsibility, 2019, p.1-13

2019

Volltextzugriff (PDF)

Constraints and Opportunities in the Mitigation of Adverse Environmental Impacts in Mineral Resources Harnessing—Some Marange Diamond Perspectives

Opportunities and Pitfalls of Corporate Social Responsibility, 2019, p.215-240

2019

Volltextzugriff (PDF)

A Conceptual and Ethical Approach to Corporate Social Responsibility in Africa’s Development Crisis: The Marange Experience

Opportunities and Pitfalls of Corporate Social Responsibility, 2019, p.197-214

2019

Volltextzugriff (PDF)

Corporate Social Responsibility in Times of Economic Crises

Opportunities and Pitfalls of Corporate Social Responsibility, 2019, p.169-181

2019

Volltextzugriff (PDF)

‘The World Against Us’: The Vulnerable Group, Marange Diamond Mines and the Corporate Social Responsibility Question

Opportunities and Pitfalls of Corporate Social Responsibility, 2019, p.123-138

2019

Volltextzugriff (PDF)

Exploring the Theoretical Basis for Stakeholder Protection in Corporate Governance

Opportunities and Pitfalls of Corporate Social Responsibility, 2019, p.35-47

2019

Volltextzugriff (PDF)

Is a Sustainable Development Affordable in Developing Countries? The Marange Diamond Fields Case

Opportunities and Pitfalls of Corporate Social Responsibility, 2019, p.183-195

2019

Volltextzugriff (PDF)

Appraisal of corporate governance in a lower middle income country: The case of Ghana

Accounting (North Vancouver), 2017-11, Vol.2 (1), p.37-44

2017

Volltextzugriff (PDF)

Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry

Respiratory research, 2019-10, Vol.20 (1), p.227-227, Article 227

2019

Volltextzugriff (PDF)

Corporate governance and credit financing in a developing economy

Corporate Ownership and Control, 2017-07, Vol.14 (4), p.340-348

2017

Volltextzugriff (PDF)

Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort

BMC pulmonary medicine, 2020-03, Vol.20 (1), p.64-64, Article 64

2020

Volltextzugriff (PDF)

Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry

Respiratory research, 2019-05, Vol.20 (1), p.105-105, Article 105

2019

Volltextzugriff (PDF)

Pooled Cardiac Safety Analysis of 48-Week Administration of Olodaterol Once Daily (QD) via Respimat® Versus Placebo and Formoterol Twice Daily (BID) in Patients With COPD

Chest, 2013, Vol.144 (4), p.713A-713B

2013

Volltextzugriff (PDF)

Efficacy of Olodaterol Once Daily (QD) via Respimat in GOLD 2/3 COPD Patients Not Receiving Background Therapy: Pooled Data From 48-Week Studies

Chest, 2013, Vol.144 (4), p.727A-727B

2013

Volltextzugriff (PDF)

Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry

Chest, 2020-05, Vol.157 (5), p.1188-1198

2020

Volltextzugriff (PDF)

Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies

International journal of chronic obstructive pulmonary disease, 2014-01, Vol.9 (default), p.629-645

2014

Volltextzugriff (PDF)

Corporate governance, structure and accountability as affected by national government infrastructure in developing countries

Corporate Ownership and Control, 2016, Vol.13 (4), p.224-231

2016

Volltextzugriff (PDF)

Hospitalizations in patients with idiopathic pulmonary fibrosis

Respiratory research, 2021-09, Vol.22 (1), p.257-257, Article 257

2021

Volltextzugriff (PDF)

One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis

Chronic obstructive pulmonary disease, 2015-09, Vol.12 (5), p.484-493

2015

Volltextzugriff (PDF)

1 – 25 von 546

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(384)
Mit Volltextzugriff
(416)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Opportunities and Pitfalls of Corporate Social Responsibility: The Marange Diamond Mines Case Study

Lessons in Financial Governance from Bowen’s Family Systems Model

Environmental Impact and CSR Responsibilities

The Socio-economic Impact of Corporate Social Responsibility on the Zimbabwe Mining Industry

CSR Implementation Challenges: Analysing the Role and Behaviour of Stakeholders

Labour Management Issues in Marange Diamond Mines

Opportunities and Pitfalls of Corporate Social Responsibility: An Introduction

Constraints and Opportunities in the Mitigation of Adverse Environmental Impacts in Mineral Resources Harnessing—Some Marange Diamond Perspectives

A Conceptual and Ethical Approach to Corporate Social Responsibility in Africa’s Development Crisis: The Marange Experience

Corporate Social Responsibility in Times of Economic Crises

‘The World Against Us’: The Vulnerable Group, Marange Diamond Mines and the Corporate Social Responsibility Question

Exploring the Theoretical Basis for Stakeholder Protection in Corporate Governance

Is a Sustainable Development Affordable in Developing Countries? The Marange Diamond Fields Case

Appraisal of corporate governance in a lower middle income country: The case of Ghana

Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry

Corporate governance and credit financing in a developing economy

Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort

Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry

Pooled Cardiac Safety Analysis of 48-Week Administration of Olodaterol Once Daily (QD) via Respimat® Versus Placebo and Formoterol Twice Daily (BID) in Patients With COPD

Efficacy of Olodaterol Once Daily (QD) via Respimat in GOLD 2/3 COPD Patients Not Receiving Background Therapy: Pooled Data From 48-Week Studies

Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry

Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies

Corporate governance, structure and accountability as affected by national government infrastructure in developing countries

Hospitalizations in patients with idiopathic pulmonary fibrosis

One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis

Suchergebnisse filtern